## **What is HCPCS code J1756?**
Iron deficiency anemia affects millions of patients worldwide, particularly those with chronic kidney disease (CKD) and other conditions that impair iron absorption or increase iron loss (Kumar et al., 2022). When oral iron supplementation proves insufficient, intravenous iron therapy becomes necessary.
HCPCS Code J1756 identifies the injection of iron sucrose at 1 mg per unit for medical billing purposes. This code specifically covers iron sucrose injection, commonly known by the brand name Venofer®, manufactured by American Regent. The HCPCS code J1756 falls under the category of drugs administered other than the oral method and involves one of several iron preparation codes available for intravenous iron therapy.
### **When is iron sucrose injection used?**
The primary diagnosis for iron sucrose injection typically includes iron deficiency anemia in various patient populations. Adult patients with chronic kidney disease, particularly patients undergoing chronic hemodialysis (both hemodialysis-dependent chronic kidney disease - HDD CKD and peritoneal dialysis-dependent chronic kidney disease - PDD CKD), frequently require iron maintenance treatment due to ongoing iron losses and reduced iron absorption (American Regent, Inc., 2021).
Other indications may include secondary diagnosis and conditions such as Crohn's disease, neoplastic disease, or complications from gastric bypass surgery, all of which can contribute to iron deficiency. Patients with end-stage renal disease (ESRD) often present with complex iron metabolism disorders that necessitate intravenous iron supplementation to maintain adequate hemoglobin levels (Rout & Aslam, 2025).
## **HCPCS code J1756 documentation requirements**
Ensure your records clearly reflect the following:
- Laboratory values documenting iron deficiency should be present. This includes serum ferritin levels, transferrin saturation percentages, and complete blood count with hemoglobin measurements.
- Documentation should demonstrate medical necessity and show that iron deficiency anemia has a significant impact on patient care and quality of life.
- There should also be the provider's clinical assessment, treatment plan, and ongoing monitoring strategy.
- All documentation must include the signature of the ordering physician or qualified healthcare provider.
## **HCPCS code J1756 billing requirements**
The most critical aspect of billing HCPCS Code J1756 involves accurate unit calculation. Since each unit represents 1 mg of iron sucrose, providers must bill the exact number of milligrams administered. For a standard 100 mg dose, the claim would include 100 units of J1756.
Claims must include the appropriate place of service code, whether the injection was administered in an office setting (code 11), outpatient hospital department (code 22), or dialysis facility. The setting impacts reimbursement rates and may affect coverage policies.
## **Other relevant codes**
- **J1750**: Injection, iron dextran, 50 mg (alternative iron preparation)
- **J1786**: Injection, imiglucerase, 10 units
- **CPT code 96365**: Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
### **References**
American Regent, Inc. (2021). Venofer® iron sucrose injection, USP. https://www.venofer.com/pdfs/PP-VE-US-0080_Patient%20Brochure_27JAN2021.pdf
Kumar, A., Sharma, E., Marley, A., Samaan, M. A., & Brookes, M. J. (2022). Iron deficiency anaemia: pathophysiology, assessment, practical management. BMJ Open Gastroenterology, 9(1), e000759. https://doi.org/10.1136/bmjgast-2021-000759
Rout, P. & Aslam, A. (2025, June 22). End-stage renal disease. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK499861/
Frequently asked questions
